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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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With preliminary data in hand, the pharmaceutical firm Roche has announced that
it will reduce the frequency of dosing in its historic Phase 3 Huntington’s disease
gene-silencing clinical trial, thus easing the burden on the participants, their
families, and clinics.
In the recently initiated trial, GENERATION HD1, volunteers will now undergo a
bi-monthly instead of a monthly spinal tap (lumbar puncture), Roche announced
in a letter to the HD community on March 21, 2019. Lumbar punctures are routine
and generally safe procedures, although they can cause side effects such as
headaches and bleeding. In GENERATION HD1 it will be a 20-minute
outpatient procedure.
Roche based the change on new data taken from 46 volunteers after nine months
into the 15-month, so-called open-label extension trial (OLE) that it started for its
drug RG6042. Those individuals previously participated in the successful Phase
1/2a clinical trial of RG6042, originally developed by Ionis Pharmaceuticals, Inc.
The drug substantially lowered the amount of mutant huntingtin protein, the
purported cause of the disease, in the patients’ cerebrospinal fluid. All OLE
participants received the drug (as opposed to 25 percent getting the placebo in the
1/2a trial).
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“The 15-month open-label extension of the Phase1/2a study is evaluating RG6042
treatment in doses every month (every four weeks) and every two months (every
eight weeks),” the Roche announcement stated. “Review of nine-month data
showed effects on lowering mutant huntingtin protein levels in the cerebral spinal
fluid that support the exploration of less frequent dosing. Based on the totality of
the data, including safety and tolerability, there appears to be no overall advantage
to treatment monthly versus every two months.”
GENERATION HD1 has three cohorts of clinical trial volunteers, known as
“arms.” The planned 660 participants at 80-90 sites around the world are
randomly assigned to one of the arms. The study is double-blinded: neither the
volunteers nor the trial physicians and their staff know which arm the volunteers
are assigned to.
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As a result of the update to the trial, all participants will undergo bi-monthly
punctures over 25 months. In “arm 1” of the study, the dosing schedule will
switch from a monthly puncture and administering the drug bi-monthly (with a
placebo in between) to a bi-monthly puncture with no placebo at all. Arm 3 will
go from getting a monthly puncture with placebo to a bi-monthly puncture with
placebo.
To test the possibility of reducing potential future drug dosing even further, arm 2
will go from a monthly puncture with the drug to a bi-monthly puncture but with
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the drug given only every four months (with a placebo in between).
“I am delighted by today’s news that the Generation HD1 protocol will be
amended to be less burdensome to trial participants, families and HD clinics
around the globe,” George Yohrling, Ph.D., the senior director of mission and
scientific affairs for the Huntington’s Disease Society of America, commented in
an e-mail. “We are all indebted to the 46 trailblazing research heroes participating
in the Phase 1/2a and open-label extension studies that showed us we could not
only lower huntingtin in humans, but could do so without monthly infusions of
RG6042. Their contributions have forever changed the landscape of HD drug
development.”
“The amended trial is good news for the HD community,” LaVonne Goodman,
M.D., the founder of Huntington’s Disease Drug Works and a physician to many
HD patents, wrote in an e-mail. “For the shorter term, it will make for fewer visits
and spinal taps for all involved in the trial. And for the longer term, if the trial at
completion is successful by clinical measures, it may further establish whether
quarterly dosing is adequate and effective. If so, that would make it easier on the
larger number of patients who would need to receive this drug life-long.”
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Simplifying the study
Dr. Goodman added: “It was fortunate that the Roche analysis and amendment
came at the very beginning of the GENERATION HD1 trial, so that changes
could be made without a major time disruption.”
A statement on the Ionis website observed that the new trial design “will greatly
simplify the operation of the study.”
Although amending the trial will cause a “slight delay” as Roche seeks regulatory
approvals, “we don’t expect this delay will change the timing of study completion,
and may even accelerate time to study completion,” the Ionis statement
concluded.
“Our team is working to rapidly activate the updated study protocol around the
world,” the Roche statement said.
Individuals who had already started GENERATION HD1, which began in
January, will be eligible to switch to GEN-EXTEND, an OLE study in which
everybody receives RG6042 (no placebo). Participants will receive drug every
two or four months.
Great news for the HD community
As the Roche statement noted, the data from the Phase 1/2a OLE do not address
the efficacy and long-term safety of the RG6042. That is the purpose of
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GENERATION HD1.
The update from Roche came in the wake of remarks by GENERATION HD1
scientific coordinator Scott Schobel, M.D., that the company is “actively
thinking” about when and how to expand research to target groups beyond the
current criterion of early- to mid-stage HD patients aged 25-65. That includes
asymptomatic gene carriers like me and sufferers of juvenile HD (click here to
read more).
The scientist-written site HDBuzz described the amended trial design as a
“surprise” but also a “good thing.”
“Clearly Roche and their partners didn’t predict that we’d be able to deliver [the
drug] only every four months when they started the GENERATION HD1 study,”
its article on the Roche statement observed. “The fact that they’ve seen data
convincing them that we can get away with it is great news for the future of this
program, and for future HD community members receiving treatment.”
HDBuzz further noted that other companies using the Ionis-Roche approach
(antisense oligonucleotides) can now “consider using longer intervals between
treatments.”
As an HD gene carrier and also a sufferer of chronic back pain, I was relieved to
learn that the number of lumbar punctures for a potential drug could be as few as
three per year.
The Roche announcement coincided with the news that the U.S.-based biotech
firm Biogen and its Japanese partner Eisai had announced that they were halting
two phase 3 clinical trials for an Alzheimer’s disease drug because an interim
analysis concluded that the compound was unlikely to benefit patients. The drug
was given through intravenous infusions.
The results of that trial once again underscored the extreme difficulty of treating
neurological disorders and the need to the need to have realistic expectations
about RG6042 (click here to read more). Not just Alzheimer’s and Huntington’s,
but also Parkinson’s, Lou Gehrig’s, and other neurological disorders lack effective
treatments.
(Disclosure: I hold a symbolic amount of Ionis shares.)
Posted by Gene Veritas at 12:10 PM
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